Trial reportAmerican journal of obstetrics and gynecology2012
Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.
Trial report in American journal of obstetrics and gynecology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.The Cochrane database of systematic reviews · 2019Pooled it
- Prenatal administration of progestogens for preventing spontaneous preterm birth in women with a multiple pregnancy.The Cochrane database of systematic reviews · 2017Pooled it
- 17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.BJOG : an international journal of obstetrics and gynaecology · 2016Pooled it
- Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis.BJOG : an international journal of obstetrics and gynaecology · 2015Pooled it
- Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth.The Cochrane database of systematic reviews · 2013Pooled it
- Relationship between plasma concentration of 17-hydroxyprogesterone caproate and gestational age at preterm delivery.American journal of obstetrics & gynecology MFM · 2023Trial
- Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.American journal of obstetrics and gynecology · 2014Trial
- What now? A critical evaluation of over 20 years of clinical and research experience with 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.American journal of obstetrics & gynecology MFM · 2023Review
- What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.Seminars in perinatology · 2016Review
- Bridging progestogens in pregnancy and pregnancy prevention.Endocrine connections · 2015Review
- Basic obstetric pharmacology.Seminars in perinatology · 2014Review
- Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.Seminars in perinatology · 2014Review
- Cervical pessaries for prevention of spontaneous preterm birth: past, present and future.Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology · 2013Review
- Qualitative and quantitative measures of various compounded formulations of 17-alpha hydroxyprogesterone caproate.American journal of obstetrics and gynecology · 2013Article
- Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth.Patient preference and adherence · 2013Article
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Funding
Abstract
objectiveWe sought to evaluate in women with twin gestation the relationship between 17-hydroxyprogesterone caproate (17-OHPC) concentration and gestational age at delivery and select biomarkers of potential pathways of drug action. STUDY
designBlood was obtained between 24-28 weeks (epoch 1) and 32-35 weeks (epoch 2) in 217 women with twin gestation receiving 17-OHPC or placebo. Gestational age at delivery and concentrations of 17-OHPC, 17-hydroxyprogesterone, progesterone, C-reactive protein (CRP), and corticotrophin-releasing hormone were assessed.
resultsWomen with higher concentrations of 17-OHPC delivered at earlier gestational ages than women with lower concentrations (P < .001). Women receiving 17-OHPC demonstrated significantly higher (P = .005) concentrations of CRP in epoch 1 than women receiving placebo but CRP values were similar in epoch 2 in both groups. A highly significant (P < .0001) positive relationship was observed between 17-OHPC concentration and progesterone and 17-hydroxyprogesterone concentrations at both epochs. Corticotropin-releasing hormone concentrations did not differ by treatment group.
conclusion17-OHPC may adversely impact gestational age at delivery in women with twin gestation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.